Results 111 to 120 of about 149,259 (318)

Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

Nephrology, Dialysis and Transplantation, 2016
Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients ...
R. Gansevoort, M. Arıcı, T. Benzing, H. Birn, G. Capasso, A. Covic, O. Devuyst, C. Drechsler, K. Eckardt, F. Emma, B. Knebelmann, Y. Le Meur, Z. Massy, A. Ong, A. Ortiz, F. Schaefer, R. Torra, R. Vanholder, A. Więcek, C. Zoccali, W. van Biesen   +20 more
semanticscholar   +1 more source

Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate whether type 2 diabetes status modifies the efficacy and safety of combining zibotentan (zibo), a selective endothelin receptor antagonist, and dapagliflozin (dapa) compared to placebo plus dapagliflozin in individuals with chronic kidney disease (CKD).
Victor Wasehuus, J. David Smeijer, Phil Ambery, Peter J. Greasley, Emma Wijkmark, David C. Wheeler, Peter Rossing, Hiddo J. L. Heerspink   +7 more
wiley   +1 more source

Autosomal dominant polycystic kidney disease and coronary artery dissection or aneurysm: A systematic review [PDF]

, 2016
Importance Autosomal dominant polycystic kidney disease (ADPKD) has been associated with cardiovascular abnormalities such as intracranial and aortic aneurysms.
Lopes, JA, Neves, JB, Rodrigues, FB
core   +1 more source

Autopsy Report with Clinical and Pathophysiologic Discussion of Autosomal Dominant Adult Polycystic Kidney Disease

Case Reports in Urology, 2014
The average weight of a kidney is approximately 135 gm, measuring on average 10 × 6 × 4 cm. In hereditary conditions, autosomal dominant and autosomal recessive polycystic kidney disease, the shape, size, and the weight can be significantly abnormal ...
Anup Hazra, Richard Siderits, Cheryl Rimmer, Noah Rolleri   +3 more
doaj   +1 more source

Evaluation of transplant benefits with the U.S. Scientific Registry of Transplant Recipients by semiparametric regression of mean residual life [PDF]

arXiv, 2023
Kidney transplantation is the most effective renal replacement therapy for end stage renal disease patients. With the severe shortage of kidney supplies and for the clinical effectiveness of transplantation, patient's life expectancy post transplantation is used to prioritize patients for transplantation; however, severe comorbidity conditions and old ...
arxiv  

Automatic Segmentation of Kidneys using Deep Learning for Total Kidney Volume Quantification in Autosomal Dominant Polycystic Kidney Disease

Scientific Reports, 2017
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common inherited disorder of the kidneys. It is characterized by enlargement of the kidneys caused by progressive development of renal cysts, and thus assessment of total kidney volume (TKV)
Kanishka Sharma, C. Rupprecht, A. Caroli, M. C. Aparicio, A. Remuzzi, Maximilian Baust, Nassir Navab   +6 more
semanticscholar   +1 more source

Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop.

American Journal of Kidney Diseases, 2020
The omission of outcomes that are of relevance to patients, clinicians and regulators across trials in autosomal dominant polycystic kidney disease (ADPKD) limits shared decision-making. The Standardized Outcomes in Nephrology - Polycystic Kidney Disease
Yeoungjee Cho, A. Tong, J. Craig, R. Mustafa, A. Chapman, R. Perrone, C. Ahn, K. Fowler, V. Torres, R. Gansevoort, A. Ong, Helen Coolican, Juliana Tze-Wah Kao, T. Harris, Talia Gutman, Jenny I. Shen, A. Viecelli, David W. Johnson, E. Au, R. El-Damanawi, C. Logeman, A. Ju, Karine E. Manera, M. Chonchol, Dwight Odland, David A. Baron, Y. Pei, B. Sautenet, A. Rastogi, Ankit Sharma, G. Rangan   +30 more
semanticscholar   +1 more source

A Novel Inhibitor of Methyltransferase SMYD2, AZ505 Protects Against Peritoneal Fibrosis in Mice

Clinical and Experimental Pharmacology and Physiology, Volume 52, Issue 7, July 2025.
AZ505, a highly selective inhibitor of SMYD2, may exhibit an antifibrotic effect in peritoneal fibrosis. ABSTRACT AZ505, a highly selective inhibitor of SMYD2, exhibits an antifibrotic effect in renal fibrosis. Its effect on peritoneal fibrosis remains unexplored.
Taijing Xu, Binbin Cui, Feng Liu, Mengjun Liu, Xiying Hou, Xuan Hong, Hualin Qi   +6 more
wiley   +1 more source

A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. [PDF]

, 2018
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the leading inheritable cause of end-stage renal disease (ESRD); however, the natural course of disease progression is heterogeneous between patients.
Bennett Wilton, Hayley, Cabrera, Maria-Cristina V, McEwan, Phil, O'Reilly, Karl, Ong, Albert CM, Robinson, Paul, Sandford, Richard, Scolari, Francesco, Walz, Gerd, Ørskov, Bjarne   +9 more
core   +5 more sources

Renal Transplantation in Autosomal Dominant Polycystic Kidney Disease [PDF]

European Medical Journal Nephrology, 2015
Autosomal dominant polycystic kidney disease (ADPKD) affects approximately 1 in 1,000 people in the general population. The natural history of ADPKD includes the progression of chronic kidney disease to end-stage renal disease (ESRD) in a large ...
Andrzej Kulesza, Longin Niemczyk, Mariusz Niemczyk   +2 more
doaj